Simon Lord - Concepedia

Author

Simon Lord

University of Oxford ORCID

Also Known As

Cheng, Wei-Chen, Lord, Simon R, S Lord, S R Lord, S. Lord, S. R. Lord, S.R. Lord, Simon LORD, Simon Lord, Simon R Lord

198

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

University of Oxford John Radcliffe Hospital Institute of Cancer Research Churchill Hospital Genomics (United Kingdom)

About

Simon Lord is an author at University of Oxford specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.1K
2	Engineering	2	2	112
3	Health Sciences	2	2	144
4	Biomedical Engineering	2	2	39
5	Biochemistry	1	1	122

Simon Lord

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Fatty Acid Uptake and Lipid Storage Induced by HIF-1α Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation Karim Bensaad, Elena Favaro, Caroline A. Lewis, Cell Reports	2014	645
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study Udai Banerji, Carla M.L. van Herpen, Cristina Saura, The Lancet Oncology Breast OncologyHer2-expressing Breast CancerMedicinePharmacologyTrastuzumab Duocarmazine	2019	549
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer Peter Hall, Daniel Swinson, David A. Cairns, JAMA Oncology	2021	176
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer Matteo Morotti, Esther Bridges, Alessandro Valli, Proceedings of the National Academy of Sciences	2019	126
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer Simon Lord, Wei-Chen Cheng, Dan Liu, Cell Metabolism Breast OncologyPathologyMetabolic Adaption PathwaysMetabolic RemodelingTumor Biology	2018	122
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). Peter Schmid, Seock‐Ah Im, Anne Armstrong, Journal of Clinical Oncology Poor Clinical OutcomesBreast OncologyImmunologyImmunoeditingPathology	2021	105
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours Geoffrey I. Shapiro, Robert Wesolowski, Craig Devoe, British Journal of Cancer	2021	98
Gene expression and hypoxia in breast cancer Elena Favaro, Simon Lord, Adrian L. Harris, Genome Medicine Breast OncologyEngineeringCancer BiologyTumor BiologyRobust Hypoxia Signature	2011	87
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. Cristina Saura, Fiona Thistlethwaite, Udai Banerji, Journal of Clinical Oncology Breast OncologyPathologyTumor BiologyHer2-positive Breast CancerMetronomic Therapy	2018	63
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial Peter Henriksen, Peter Hall, Iain R. Macpherson, Circulation	2023	63

Page 1